AbbVie (ABBV) Acquires Apogee for $10.9 Billion Eczema Drug
Published on · Source: marketwatch.com
AI Summary
Summarized by AI from the source belowAbbVie (ABBV) announced its acquisition of Apogee Therapeutics for $10.9 billion. The focus of this acquisition is Apogee's development of an experimental drug for atopic dermatitis, a type of eczema. This move is significant for AbbVie as it expands its portfolio in dermatological treatments. The transaction underscores the ongoing trend of consolidations in the biotech sector to enhance product pipelines.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About AbbVie Inc. (ABBV)
AbbVie is a research-based pharmaceutical company with a portfolio spanning immunology, oncology, and neuroscience.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier ABBV news
- AbbVie (ABBV) Acquires Apogee for $10.9 Billion in Immunology Deal
- Dividend Portfolio Return: $43,770 Annual Income and $7,515 Tax Impact
- Johnson & Johnson (JNJ) Q1 2026 Revenue Hits $24.06 Billion
- AbbVie (ABBV) Q3 Earnings Beat Estimates on Immunology Drug Sales
- AbbVie (ABBV) Tops Quarterly Estimates with $15 Billion Revenue
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
